Ashraf Hanna, Ph.D., M.D.
Chief Executive Officer
Ashraf Hanna is a biopharmaceutical executive with over 20 years of industry experience. Dr. Hanna was previously the Vice President, Commercial and Medical Affairs Finance at Genentech, and CFO of the Genentech Foundation. He also held leadership roles as VP of Genentech’s Alliance Management and Portfolio Planning groups, and was a member of Genentech’s Commercial Leadership Committee (CLC).
Dr. Hanna previously headed strategy and business development at Tanox, where he successfully partnered their lead drug with Novartis and Genentech, and prior to that was at McKinsey and Company. He has a Ph.D. in Physics from Harvard University and an M.D. from the University of Massachusetts. He studied Physics and Economics at the University of Chicago as an undergraduate.
Valeria Fantin, Ph.D.
Chief Scientific Officer
Dr. Fantin is a biopharmaceutical leader with over a decade of experience in exploratory biology and oncology drug discovery and development. Prior to joining ORIC Pharmaceuticals, she was Vice President of Tumor Cell Biology at Pfizer, responsible for advancing small molecules from target validation to Phase 2 proof-of-concept. Dr. Fantin was also responsible for identifying business development opportunities and leading strategic alliances to broaden Pfizer’s efforts in oncology research. Prior to joining Pfizer in 2011, Dr. Fantin held leadership positions at Agios Pharmaceuticals where she created and advanced an exploratory program of novel cancer metabolism targets into drug discovery, and led the execution of the company’s flagship isocitrate dehydrogenase program. Her earlier career as a researcher included positions focused on epigenetics and kinase drug discovery projects with Merck Research Laboratories and ARIAD Pharmaceuticals. She has contributed to the discovery of numerous compounds currently under clinical evaluation and the development of Zolinza® (vorinostat) and Ibrance® (palbociclib). In 2012, Dr. Fantin was awarded the Rising Star Award by the Healthcare Businesswomen’s Association. Dr. Fantin completed postdoctoral training in cancer metabolism and signal transduction at Harvard Medical School and the Howard Hughes Medical Institute, and earned her Ph.D. in molecular and cellular biology from Dartmouth Medical School.
Darcy Mootz, Ph.D.
Chief Business Officer
Dr. Mootz is a biopharmaceutical executive with over a dozen years of experience spanning multiple areas of the life sciences industry. Prior to joining ORIC, she was Vice President of Corporate Development at Achaogen, where she led corporate development & alliance management, served as the project team leader for the company’s lead asset, and contributed to successful financings. Prior to Achaogen, she held a variety of roles across corporate development, marketing, and strategic planning at BiPar Sciences, Genentech, and L.E.K. Consulting. Key experiences include contributing to the development and commercialization of several products (e.g., Avastin® and plazomicin, an antibiotic currently in Phase 3), the sale of BiPar Sciences to Sanofi, and the IPO of Achaogen. Dr. Mootz holds a B.S. in biology from Duke University and a Ph.D. in biochemistry from Harvard University.